2022
The worldwide impact of telemedicine during COVID-19: current evidence and recommendations for the future
Omboni S, Padwal RS, Alessa T, Benczúr B, Green BB, Hubbard I, Kario K, Khan NA, Konradi A, Logan AG, Lu Y, Mars M, McManus RJ, Melville S, Neumann CL, Parati G, Renna NF, Ryvlin P, Saner H, Schutte AE, Wang J. The worldwide impact of telemedicine during COVID-19: current evidence and recommendations for the future. Connected Health 2022, 1: 7-35. PMID: 35233563, PMCID: PMC7612439, DOI: 10.20517/ch.2021.03.Peer-Reviewed Original ResearchManagement of patientsSurveillance of patientsContinuity of careMultiple chronic diseasesQuality of careRoutine clinical useFrail patientsPatient awarenessChronic diseasesCurrent evidencePatientsHealthcare professionalsClinical useIll peoplePopulation subgroupsHealthcare systemHealthcare servicesTimely identificationReimbursement plansCOVID-19COVID-19 pandemicTelemedicineSpread of diseaseDiseaseTraditional healthcare services
2019
P834Secondary prevention medications of cardiovascular diseases in China: findings from China PEACE million persons project
Lu J, Zhang L, Lu Y, Su M, Li X, Li J, Liu J, Zhang H, Nasir K, Masoudi F, Krumholz H, Zheng X. P834Secondary prevention medications of cardiovascular diseases in China: findings from China PEACE million persons project. European Heart Journal 2019, 40: ehz747.0433. DOI: 10.1093/eurheartj/ehz747.0433.Peer-Reviewed Original ResearchSecondary prevention medicationsIschemic heart diseasePrevention medicationsAnti-platelet drugsCardiovascular diseaseMultivariable mixed modelsIschemic strokePopulation subgroupsCardiac Events Million Persons ProjectHistory of IHDPrognosis of CVDMillion Persons ProjectHealth behavior factorsSecondary prevention drugsCause of deathCurrent usePublic health programsPersons ProjectNational Health CommissionCurrent smokersSecondary preventionMedication useMultivariable analysisChina PatientPrevention drugs